The binary catalysts are the November and December 2026 PDUFA decisions for bezuclastinib in GIST and NonAdvSM. Positive outcomes would validate a multi-billion-dollar peak sales opportunity; any delay or complete response letter would reset the timeline and likely trigger a significant drawdown given the current $7.2B market cap, which already prices in approval. Monitor FDA advisory committee meeting announcements and the AdvSM NDA filing for additional near-term volatility.
Price Chart
Executive Summary
Cogent Biosciences reported a wider net loss of $96.4M for Q2 2026 vs. $73.5M a year ago, reflecting scaling R&D and commercial readiness costs as it approaches two PDUFA dates in late 2026 (GIST November 30, NonAdvSM December 30). The company ended the quarter with $792.3M cash and raised $73.6M in gross proceeds from an ATM post-quarter, extending its runway into late 2028. With no revenue or consensus EPS available for the period, the filing's impact hinges on the binary regulatory catalysts ahead, not the financial results themselves.
Key Facts
- Net loss widened to $96.4M in Q2 2026 from $73.5M in Q2 2025, driven by increased R&D ($70.8M vs. $62.2M) and G&A ($31.8M vs. $13.4M) related to commercial build-out.
- Cash, cash equivalents and marketable securities were $792.3M at June 30, 2026; an additional $73.6M gross proceeds from ATM facility after quarter-end bring pro-forma cash to $865.9M.
- FDA accepted NDA with priority review for bezuclastinib in GIST (PDUFA November 30, 2026); NDA for NonAdvSM accepted with PDUFA December 30, 2026.
- AdvSM NDA submitted to FDA on June 30, 2026; APEX pivotal trial showed 65% ORR in 68 evaluable AdvSM patients.
- Onboarded full commercial field team; company expects cash runway into late 2028 including through potential launches.
- Phase 3 PEAK data presented at ASCO: bezuclastinib+sunitinib reduced risk of progression or death by 50% vs. sunitinib alone (HR 0.50; mPFS 16.5 vs. 9.2 months).
Financial Impact
No revenue generated; net loss expanded by ~31% YoY; cash burn $108.5M in H1 2026; pro-forma cash $865.9M sufficient into late 2028.
Risk Factors
- Clinical/regulatory risk: FDA could issue a complete response letter (CRL) for GIST or NonAdvSM, delaying or blocking approval.
- Commercial risk: Launch execution and market access for a rare-disease drug in a competitive SM/GIST landscape (novartis/Blueprint avapritinib).
- Cash burn risk: Pre-revenue, widening losses may require additional capital before meaningful product revenue is generated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341315 |
| Document: cogt-20260810.htm | 0001193125-26-341315 |
| Document: 0001193125-26-341315-index-headers.html | 0001193125-26-341315 |
| Document: 0001193125-26-341315-index.html | 0001193125-26-341315 |
| Document: 0001193125-26-341315.txt | 0001193125-26-341315 |
| 8-K Data (Synthetic) | 0001193125-26-341315 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 10, 2026 7w ago | Press Release | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 9, 2026 7w ago | Institutional Cluster | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
May 30, 2026 17w ago | Press Release | $34.81 $38.70 | ▲ +11.18% | ▲ +12.47% | $31.02 (−10.89%) |
May 28, 2026 18w ago | Press Release | $35.38 $38.10 | ▲ +7.69% | ▲ +10.83% | $31.02 (−12.32%) |
May 5, 2026 21w ago | 8-K | $36.98 $32.76 | ▼ −11.41% | ▼ −16.37% | $31.02 (−16.12%) |
Apr 17, 2026 24w ago | Press Release | $37.25 $34.19 | ▼ −8.21% | ▼ −13.59% | $31.02 (−16.72%) |
Apr 1, 2026 26w ago | Press Release | $35.24 $35.87 | ▲ +1.79% | ▼ −7.93% | $31.02 (−11.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access